18,452 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Graybill Wealth Management LTD.

Graybill Wealth Management LTD. purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 18,452 shares of the medical instruments supplier's stock, valued at approximately $4,227,000.

Several other large investors also recently modified their holdings of the stock. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Hara Capital LLC grew its stake in shares of Becton, Dickinson and Company by 26.4% in the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock valued at $76,000 after buying an additional 70 shares during the period. EverSource Wealth Advisors LLC increased its position in Becton, Dickinson and Company by 63.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,262 shares of the medical instruments supplier's stock valued at $286,000 after buying an additional 491 shares in the last quarter. Farther Finance Advisors LLC increased its position in Becton, Dickinson and Company by 42.9% in the 4th quarter. Farther Finance Advisors LLC now owns 3,144 shares of the medical instruments supplier's stock valued at $713,000 after buying an additional 944 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in Becton, Dickinson and Company by 5.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 86,759 shares of the medical instruments supplier's stock worth $19,683,000 after acquiring an additional 4,838 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BDX. Raymond James Financial downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday, May 2nd. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price target for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and a consensus target price of $219.22.

Becton, Dickinson and Company Stock Up 0.7%

Becton, Dickinson and Company stock traded up $1.18 during midday trading on Monday, hitting $177.15. 6,386,593 shares of the stock were exchanged, compared to its average volume of 2,603,202. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The business's 50-day moving average price is $172.33 and its 200-day moving average price is $205.76. The stock has a market capitalization of $50.77 billion, a price-to-earnings ratio of 33.81, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. Becton, Dickinson and Company's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.17 earnings per share. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.35%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.